MedTechPost

Roche gains FDA authorization for automated mass spectrometry

The cobas pro i 601 and Ionify Gabapentin combination adds therapeutic drug monitoring to the US offering.

MedTechPost.com Newsroom · November 16, 2026 at 9:00 AM
Illustration: AI-generated

Roche has reported FDA De Novo authorization for cobas pro i 601 with the Ionify Gabapentin assay. Part of the cobas Mass Spec solution, the combination extends testing into therapeutic drug monitoring.

The company aims to combine mass spectrometry with automated, standardized routine-laboratory workflows. Traditional methods frequently require specialist staff and manual steps, according to the announcement. The gabapentin test joins existing US applications for vitamin D and steroid hormones.

Context and evidence

Roche also cites an authorized Predetermined Change Control Plan allowing potential expansion by up to 22 Ionify assays when requirements are met. Those additional tests are explicitly not yet available. An authorized development pathway is not immediate launch of the entire future menu.

What it means

Clinical laboratories can assess how a complex analytical technique fits routine operations. Reductions in staffing effort and turnaround times must be evaluated against local workflows and verifiable operational data.

Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.

Read the full article